- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04631679
Investigation of the Wash-out Effect of Intravenous Iron by Cell Savers (WASH-OUT) (WASH-OUT)
Investigation of the Wash-out Effect of Intravenous Iron by Cell Savers
Study Overview
Status
Detailed Description
Because of the short time frame between iron therapy to procedure in cardiac surgery due to the need to perform cardiac revascularization, the investigators aim to investigate how much of the iron compound ferric carboxymaltose is being stored within the iron storage cells of the human body, and how much remains in the patient's own blood at the time point of surgery. The terminal elimination half-life time of ferric carboxymaltose is known to be approximately 7.1 to 12.1 hours, with peak serum ferritin levels at 48h to 120h after administration. When high blood loss in a surgical procedure is expected, such as in cardiosurgical procedures, the usage of autologous cell salvage, so called "Cell Saver", is considered standard, good practice. The blood that is lost during surgery is collected and after a specified blood separation wash, being retransfused in form of concentrated red blood cells.
This trial aims to examine whether Cell Saver usage might recover high molecular iron complexes such as ferric carboxymaltose lost by bleeding intraoperatively or wash out these molecules.
If amount of lost blood during surgery is too low, that Cell Saver usage would not be possible otherwise, averagely 300ml of blood from the heart-lung machine are added to the cell saver to enable the process of cell saver use.
For each participant, 7 samples will be taken. The samples include patient's blood samples and samples from cell saver compartments (Washing solution, concentrates) as well as from the heart-lung-machine, in detail:
- arterial patient's blood, preoperative, day of procedure, prior to surgery
- blood from the heart-lung machine, intraoperative 30 minutes prior to end of use of the heart-lung machine, day of procedure
- Cell Saver: washed-out compounds, intraoperative, after end of use of heart-lung machine, day of procedure
- Cell Saver: produced red blood cell concentrate, intra- or postoperative, after end of use of heart-lung machine, day of procedure
- arterial patient's blood, postoperative, day of procedure
- venous patient's blood, 3. day postoperative
- venous patient's blood, 7. day postoperative
By liquid chromatography inductively coupled plasma mass spectrometry (LC-ICP-MS) levels of ferric carboxymaltose are examined
- in the patient's blood prior to surgery to determine the amount of ferric carboxymaltose within the patients blood prior to surgery, and after a certain time after the intravenous Infusion of ferric carboxymaltose (12-96 hours).
- pre- and postoperatively and in cell saver compartments. If ferric carboxymaltose is detected in the washing solution of the Cell Saver System and not within the stored red blood cell concentrate, ferric carboxymaltose is washed out by the cell saver.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Muenster, Germany, 48149
- Dept. of Anesthesiology, Intensive Care and Pain Medicine, UKM
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- scheduled cardiosurgical procedure such as valve surgery, aortocoronary bypass or both combined within 1-4 days after anesthesiological/PBM clinic
- for Group A: diagnosed anemia (hemoglobin levels below 13g/dL in men and 12g/dL in women) and iron-deficiency (transferrin saturation below 20% or ferritin serum level below 300μg/L), treatment with 500mg of ferric carboxymaltose (FerInject® 50 mg/ml, 10 ml, Vifor Pharma Group, Switzerland).
Exclusion Criteria:
- contraindication for intravenous iron therapy: severe infections, hepatocellular carcinoma, liver metastases, acute severe asthma, a simultaneous oral iron medication, another intravenous iron preparation, iron overload, chronic renal failure with regular intravenous iron substitution during dialysis treatment, age ≤18 years, pregnancy, lactation and being allergic to iron
- elevated C-reactive protein (CRP) and leukocyte levels (cut-off level for leucocytes for men was <10.9x10^3/μl and for women <12.68x10^3/μl, respectively)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Group A: anemic patients with iron treatment
For Group A anemic patients (hemoglobin levels below 13g/dL in men and 12g/dL in women) with iron deficiency (transferrin saturation below 20% or ferritin serum level below 300μg/L) are screened in the Anesthesia pre-assessment clinic 1-4 days prior to cardiosurgical procedure (valve repair/implementation, aortocoronary bypass or a combination of both) and are treated with a single intravenous dose of 500 milligrams of ferric carboxymaltose in 100ml 0,9% sodium chloride solution as iron supplementation directly (FerInject® 50 mg/ml, 10 ml, Vifor Pharma Group, Switzerland).
|
Group B: non-anemic patients without iron treatment
For Group B, non-anemic patients (hemoglobin levels above 13g/dL in men and 12g/dL in women) without iron deficiency (transferrin saturation above 20%, ferritin serum levels above 300μg/L) are screened in the Anesthesia pre-assessment clinic 1-4 days prior to cardiosurgical procedure (valve repair/implementation, aortocoronary bypass or both combined) and are not treated with iron supplementation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ferric Carboxymaltose levels (µg/mL)
Time Frame: day of surgery to seven days after surgery
|
Ferric Carboxymaltose levels in samples withdrawn from patient's blood, red blood cell concentrate of Cell Saver, heart-lung machine and washing solution prior to and after surgical procedure (µg/mL-Ferric carboxymaltose/plasma volume)
|
day of surgery to seven days after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Donor red blood cell concentrates
Time Frame: Beginning till end of surgery
|
Additional substitution of donor red blood cell concentrates
|
Beginning till end of surgery
|
Ferritin (ng/ml)
Time Frame: prior to intravenous iron supplementation
|
Ferritin levels before intravenous iron supplementation
|
prior to intravenous iron supplementation
|
Ferritin (ng/ml)
Time Frame: point of intravenous iron supplementation until surgery
|
Ferritin levels after intravenous iron supplementation
|
point of intravenous iron supplementation until surgery
|
Ferritin (ng/ml)
Time Frame: 3 days after surgery
|
Ferritin levels after intravenous iron supplementation
|
3 days after surgery
|
Ferritin (ng/ml)
Time Frame: 7 days after surgery
|
Ferritin levels after intravenous iron supplementation
|
7 days after surgery
|
Hemoglobin levels (mg/dl)
Time Frame: prior to intravenous iron supplementation, 1 to 4 days prior to surgery
|
Delta Hemoglobin levels between prior to IV iron substitution until surgery
|
prior to intravenous iron supplementation, 1 to 4 days prior to surgery
|
Hemoglobin levels (mg/dl)
Time Frame: 3 days after surgery
|
Hemoglobin levels after surgery
|
3 days after surgery
|
Hemoglobin levels (mg/dl)
Time Frame: 7 days after surgery
|
Hemoglobin levels after surgery
|
7 days after surgery
|
Intraoperative blood loss (ml)
Time Frame: Beginning till end of surgery
|
Blood volume lost while surgical procedure
|
Beginning till end of surgery
|
Blood volume balance (ml)
Time Frame: Beginning till end of surgery
|
Delta of intraoperatively given (infusions, transfusions) and lost (bleeding, withdrawn from heart-lung machine) volumes
|
Beginning till end of surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Andrea U Steinbicker, MD, MPH, Dept. of Anesthesiology, Intensive Care and Pain Medicine, University Hospital of Münster
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 09-Antl-19
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Hospital Universitario Dr. Jose E. GonzalezCompletedPernicious Anemia | Megaloblastic Anemia NosMexico
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
Abdelwahed, Mai Mahmoud Mohamed, M.D.UnknownAnemia During PregnancyEgypt
-
University of California, DavisInstituto Mexicano del Seguro Social; Thrasher Research Fund; Mexican National... and other collaboratorsCompleted
-
Incyte CorporationActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
-
Cornell UniversityUniversity of California, Los AngelesCompletedPregnancy Anemia | Newborn; AnemiaUnited States
-
Peking Union Medical College HospitalRecruiting